NOVO NORDISK – Rybelsus (Semaglutide) – 14 mg Tablets
Supplied in a box containing 10 x 14 mg oral tablets.
Active Ingredient: Semaglutide.
Indications:
Rybelsus is used in adults with type 2 diabetes to improve blood sugar control when lifestyle changes alone are insufficient. It may also assist with weight management as part of a comprehensive diabetes care plan.
Administration:
Taken orally once daily on an empty stomach, at least 30 minutes before the first food, drink, or any other medication, with no more than 4 ounces of water. The 14 mg dose is typically prescribed following the 7 mg dose to further optimize blood glucose control, as directed by a healthcare provider.
Effects:
Rybelsus is a GLP-1 receptor agonist that enhances insulin secretion, decreases glucagon levels, and slows gastric emptying, leading to better blood sugar regulation and potential appetite reduction, which may aid in weight management.
Side Effects:
Common side effects include nausea, stomach discomfort, and decreased appetite. Rare but serious side effects can include pancreatitis, kidney issues, or severe gastrointestinal symptoms.
Contraindications:
Not suitable for individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disorders. Regular monitoring of blood glucose and other health markers is recommended to ensure effective and safe treatment.